Navigation Links
23ème congrès européen sur l'Hypertension et la Protection Cardiovasculaire
Date:6/25/2013

lope, Chef de l'Unité Hypertension à l'Hôpital du 12 Octobre de Madrid en Espagne, et investigateur principal de l'étude SEVITENSION. "Les études post-commercialisation telles que celle-ci fournissent des données importantes pour aider les médecins à choisir les meilleures options thérapeutiques afin de prendre en charge de manière plus efficace et plus pratique l'hypertension artérielle, et ainsi de mieux protéger les patients. Cette amélioration potentielle dans la prise en charge de l'HTA aidera les médecins à atteindre l'objectif ambitieux de contrôler la pression artérielle chez au moins 70% des patients hypertendus d'ici 2015."

Les médicaments tels que les inhibiteurs de l'enzyme de conversion de l'angiotensine (IEC) réduisent la pression artérielle en inhibant l'activité du système rénine-angiotensine (SRA). Une classe plus récente de médicaments antihypertenseurs, appelés antagonistes du récepteur de l'angiotensine (ARA II) réduit aussi la pression artérielle en inhibant le SRA, et offre l'avantage de provoquer moins d'effets secondaires que les IEC, notamment la toux.[7]

Daiichi Sankyo soutient activement la recherche sur les antihypertenseurs, et a développé toute une gamme de médicaments à base de l'ARA II olmésartan. Un de ces produits, l'association fixe olmésartan/amlodipine (Sevikar®), a été utilisée pour tenter de répondre à une question clinique importante : est-ce que l'association de deux médicaments composée d'un ARA II tel que l'olmésartan, et de l'amlodipine peut réduire la pression artérielle centrale aussi efficacement que l'association du périndopril et de l'amlodipine ? Cette question a &#
'/>"/>

SOURCE Daiichi Sankyo Europe GmbH
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
2. Experts Launch the Alliance for Fertility Preservation at the International Society for Fertility Preservations 2nd World Congress
3. Global Leaders in Advanced Biofuels Industry Urge Congressional Leaders to Extend Critical Tax Provisions
4. Nation Must Invest in Biomedical Research/Health Workforce, AAHC President Tells Congress
5. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
6. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
7. ETEX Corporation to present at the 9th World Biomaterial Congress
8. Discovery Labs to Present AFECTAIR® Data at European Congress on Pediatric and Neonatal Ventilation
9. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
10. The Legends that Contributed to Silicon Valleys Eminence Assemble for Frost & Sullivans Growth, Innovation and Leadership 2012 Congress
11. BIOCOM Announces Endorsement in 52nd Congressional District Race
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... A new way to produce engineered ... current skin grafting technologies, it also speeds up the ... outlined in the October issue of STEM CELLS Translational ... injuries that result from severe burns and chronic wounds. ... regenerative elements. These wounds heal by contraction, with epithelization ...
(Date:10/25/2014)... October 24, 2014 Oramed Pharmaceuticals ... company focused on the development of oral drug delivery ... Kidron will present at FireRock Capital,s Micro-Cap Conference. ... Micro-Cap Conference ,Date: Tuesday, October 28, 2014 ,Time: 9:15am ... New York City , About ...
(Date:10/25/2014)...  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or ... International Symposium on Thymosins in Health and Disease in ... "When thymosin beta 4 (TB4) linked with rhodamine (a ... in a rodent model of stroke, it was visualized ... (the functional tissue of the brain).   The leakage of ...
(Date:10/25/2014)... 24, 2014 Research and Markets ... by Product , Research Area & by End User ... offering. In this report, the global ... research areas, and end users. The product segments of ... instruments & consumables, kits, and reagents. The subsegments of ...
Breaking Biology Technology:New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3
... (OTC Bulletin Board: CHBT) (,China-Biotics", "the,Company"), a leading ... and distribution of probiotics products,today announced its financial ... year, ended June 30, 2008., First ... 19.5% year-over-year to $11.4 million -- Gross ...
... ... Aug. 14 Senetek PLC (OTC,Bulletin Board: SNKTY), a Life ... science of healthy aging, today announced,financial results for the quarter ... June 30, 2008 was $691,000, compared with,$471,000 reported in the ...
... drugs and devices that have ... the quality of human life -, PALO ALTO, Calif., ... announced that its chronic angina therapy,Ranexa(R) (ranolazine extended-releases tablets) has ... 2008 award which honors the,best pharmaceutical agent and best biotechnology ...
Cached Biology Technology:China-Biotics, Inc. Reports First Quarter 2009 Financial Results 2China-Biotics, Inc. Reports First Quarter 2009 Financial Results 3China-Biotics, Inc. Reports First Quarter 2009 Financial Results 4China-Biotics, Inc. Reports First Quarter 2009 Financial Results 5China-Biotics, Inc. Reports First Quarter 2009 Financial Results 6China-Biotics, Inc. Reports First Quarter 2009 Financial Results 7China-Biotics, Inc. Reports First Quarter 2009 Financial Results 8China-Biotics, Inc. Reports First Quarter 2009 Financial Results 9China-Biotics, Inc. Reports First Quarter 2009 Financial Results 10China-Biotics, Inc. Reports First Quarter 2009 Financial Results 11Senetek PLC Reports Second Quarter 2008 Financial Results 2Senetek PLC Reports Second Quarter 2008 Financial Results 3CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award 2CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award 3
(Date:10/16/2014)... (October 16, 2014) – Post-menopausal women experienced improvements ... hormone levels or genital bleeding, after 12 weeks ... investigational fermented soy germ-based nutritional supplement previously shown ... a new peer-reviewed pilot study reported in a ... annual scientific meeting. , "These data documented ...
(Date:10/15/2014)... admitted Johannes Gutenberg University Mainz (JGU) as a ... continues to maintain a significant nationwide standing in ... acceptance of Johannes Gutenberg University Mainz as a ... in the national and international competition for the ... Rhineland-Palatinate can be proud that Mainz University has ...
(Date:10/15/2014)... 2014   Neurotechnology , a provider of ... of the VeriLook Surveillance 3.0 software development ... biometric face identification using live video streams from ... new version not only identifies faces in a ... while they are moving through the video frame. ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3
... A custom-built, $2.5 million "split magnet" system with the potential ... made its debut at the National High Magnetic Field Laboratory ... at 25 tesla, easily besting the 17.5 tesla French record ... for early 20th-century inventor and engineer Nikola Tesla, is a ...
... as a preventative measure only achieve a short-term effect with ... up with even more aphids than untreated fields. This has ... of Wrzburg in the scientific journal PLoS One . ... triticale fields? This is what the biologists at the Department ...
... widely known PSA blood test for prostate cancer in men ... for breast cancer, the most common form of cancer in ... the ACS journal Analytical Chemistry . Chien Chou ... the test also is a potential biomarker of breast cancer ...
Cached Biology News:25 Tesla, world-record 'split magnet' makes its debut 225 Tesla, world-record 'split magnet' makes its debut 3Fewer aphids in organic crop fields 2
normal human fibroblasts Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
3T3 cells (RSV-transformed) Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
PC12 (rat phaeochromocytoma) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Peptide-affinity Purified Polyclonal Antibody to Olfactory Receptor, Family 2, Subfamily H, Member 3...
Biology Products: